INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 454m ago
HOUSE PTR53m ago
SEC 13F53m ago
ROBINHOOD CHAIN53m ago
SEC FORM 4/Grant or awardVerified data

Hunter James Randolph Jr reported TNXP

Director · Tonix Pharmaceuticals Holding Corp. · Tonix Pharmaceuticals Holding Corp. — Stock Option

Side
A
Value
—
Shares
22.7K
Price
—
Executed
May 12, 2026
Disclosed
May 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 12 executedMay 14, 2026 disclosed

TNXP · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TNXP

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    41
    BH
    Bagger Richard HDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Open-market purchase
    		BUY$13K
    1,000 sh
    		Aug 20, 2026Aug 24, 2026
    traded Aug 20, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BH
    Bagger Richard HDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    OY
    Olukotun Adeoye YDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BS
    Bell Margaret SmithDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SN
    Stillwell Richard NewcombDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TJ
    Treco JamesDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GL
    Grange David LDirector
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TE
    Taylor Carolyn E.Director
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    22.7K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    36
    LS
    Lederman SethDirector, Chief Executive Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Open-market purchase
    		BUY$63K
    5,000 sh
    		Mar 31, 2026Apr 1, 2026
    traded Mar 31, 2026
    		+1dSEC FORM 4

    Evidence

    44
    LS
    Lederman SethDirector, Chief Executive Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Open-market purchase
    		BUY$223K
    15.0K sh
    		Mar 18, 2026Mar 18, 2026
    traded Mar 18, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SM
    Sullivan Gregory MChief Medical Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LS
    Lederman SethDirector, Chief Executive Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    134.5K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ME
    Morris Jessica EdgarChief Operating Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ME
    Morris Jessica EdgarChief Operating Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Saenger BradleyChief Financial Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SM
    Sullivan Gregory MChief Medical Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FS
    Fogarty SiobhanChief Technology Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    FS
    Fogarty SiobhanChief Technology Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LS
    Lederman SethDirector, Chief Executive Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    134.5K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SB
    Saenger BradleyChief Financial Officer
    TNXPTonix Pharmaceuticals Holding Corp.
    Grant or award
    		A—
    39.0K sh
    		Feb 24, 2026Feb 26, 2026
    traded Feb 24, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001999371-26-010751
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 12, 2026
    Published
    May 14, 2026
    Ingested by INSIDER
    Nov 5, 03:58 UTC
    Last re-read
    Nov 5, 03:58 UTC

    Extracted facts

    Filer
    Hunter James Randolph Jr
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Tonix Pharmaceuticals Holding Corp. — Stock Option
    Ticker
    TNXP
    Shares
    22.7K
    Price per share
    $0
    Execution date (reported)
    May 12, 2026
    Owned after transaction
    22.7K shares
    Days from execution to publication
    2

    What this establishes

    Hunter James Randolph Jr filed this Form 4 reporting a grant or award of TNXP on May 12, 2026. It became public on May 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Hunter James Randolph Jrcik:0002071788
    Issuer
    Tonix Pharmaceuticals Holding Corp.cik:0001430306

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.